"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.005.600 D08.244.453.491.372 D08.811.682.690.708.170.010.600 D08.811.682.690.708.170.450.368 D12.776.422.220.453.010.600 D12.776.422.220.453.491.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP2D6
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2017 | 0 | 3 | 3 |
| 2018 | 6 | 1 | 7 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. Clin Transl Sci. 2021 01; 14(1):153-162.
-
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe? Cardiol Rev. 2020 Sep/Oct; 28(5):266-271.
-
COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap! Circulation. 2020 07 07; 142(1):7-9.
-
Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele. Pharmacogenomics. 2019 07; 20(10):719-729.
-
Comparing PyroMark Q24 Pyrosequencing and MALDI-TOF MS for Identification of CYP2D6*10. Clin Lab. 2019 May 01; 65(5).
-
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019 01 17; 380(3):215-228.
-
Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. Malar J. 2018 Nov 15; 17(1):427.
-
Prevalence of CYP2D6*4 1934G/A polymorphism in Western Indian HIV patients. APMIS. 2018 Nov; 126(11):842-851.
-
An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. Bioanalysis. 2018 Oct 01; 10(19):1577-1590.
-
CYP2D6 genotypes in revolving door patients with bipolar disorders: A case series. Medicine (Baltimore). 2018 Sep; 97(37):e11998.